The promise of futility trials in neurological diseases-Reference-Cited by-同舟云学术

The promise of futility trials in neurological diseases

Published:2015-03-17 Issue:5 Volume:11 Page:300-305
ISSN:1759-4758
Container-title:Nature Reviews Neurology
language:en
Short-container-title:Nat Rev Neurol

Author:

Koch Marcus W.,Korngut Lawrence,Patry David G.,Agha-Khani Yahya,White Christopher,Sarna Justyna R.,Yeung Michael,Yong V. Wee,Heng Daniel Y. C.,Cutter Gary,Metz Luanne

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Clinical Neurology

Link

http://www.nature.com/articles/nrneurol.2015.34.pdf

Reference68 articles.

1. Van Glabbeke, M. et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur. J. Cancer 38, 543–549 (2002).

2. A'Hern, R. P. Sample size tables for exact single-stage phase II designs. Stat. Med. 20, 859–866 (2001).

3. Gehan, E. A. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J. Chronic Dis. 13, 346–353 (1961).

4. Fleming, T. R. One-sample multiple testing procedure for phase II clinical trials. Biometrics 38, 143–151 (1982).

5. Simon, R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 10, 1–10 (1989).

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving the efficiency of clinical trials in multiple sclerosis;Multiple Sclerosis Journal;2023-08

2. An Online Weight Loss Intervention for People With Obesity and Poorly Controlled Asthma;The Journal of Allergy and Clinical Immunology: In Practice;2022-06

3. mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double‐Blind, Placebo‐Controlled Futility Trial and 1‐Year Biomarker Longitudinal Analysis;Movement Disorders;2022-01-18

4. Hydroxychloroquine for Primary Progressive Multiple Sclerosis;Annals of Neurology;2021-10-15

5. Repurposing Domperidone in Secondary Progressive Multiple Sclerosis;Neurology;2021-03-23